Atea Pharmaceuticals (AVIR) Other Gross PP&E Adjustments (2019 - 2026)
Atea Pharmaceuticals' Other Gross PP&E Adjustments history spans 8 years, with the latest figure at -$478000.0 for Q1 2026.
- Quarterly Other Gross PP&E Adjustments rose 56.27% to -$478000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$478000.0 through Mar 2026, up 56.27% year-over-year, with the annual reading at -$22.6 million for FY2025, 2.93% down from the prior year.
- Other Gross PP&E Adjustments came in at -$478000.0 for Q1 2026, up from -$22.6 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$478000.0 in Q1 2026 to a low of -$22.6 million in Q4 2025.
- The 5-year median for Other Gross PP&E Adjustments is -$2.1 million (2023), against an average of -$5.7 million.
- Year-over-year, Other Gross PP&E Adjustments plummeted 1012.78% in 2022 and then skyrocketed 56.27% in 2026.
- Atea Pharmaceuticals' Other Gross PP&E Adjustments stood at -$12.6 million in 2022, then plummeted by 40.46% to -$17.7 million in 2023, then dropped by 23.75% to -$21.9 million in 2024, then decreased by 2.93% to -$22.6 million in 2025, then soared by 97.88% to -$478000.0 in 2026.
- Per Business Quant, the three most recent readings for AVIR's Other Gross PP&E Adjustments are -$478000.0 (Q1 2026), -$22.6 million (Q4 2025), and -$789000.0 (Q3 2025).